Immunovant director Atul Pande sells $59,699 in shares By Investing.com

Immunovant Inc. () Director Atul Pande sold shares of the company’s common stock totaling $59,699 on July 24, 2026, according to a recent filing with the Securities and Exchange Commission.

The transaction involved the disposition of 1,500 shares at a price of $39.8 per share. This sale was executed pursuant to a Rule 10b5-1 Plan, which Pande adopted on December 26, 2025. The sale price is near the company’s 52-week high of $41.23, reflecting Immunovant’s strong performance with shares up 133% over the past year. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, placing it among companies on the most overvalued list.

Prior to the sale, Mr. Pande acquired the same number of shares through the exercise of stock options. These 1,500 shares were acquired at an exercise price of $8.43 per share, amounting to a total value of $12,645. These options were part of an award of stock options to purchase common shares that were fully vested.

Following these transactions, Atul Pande directly beneficially owns 116,731 shares of Immunovant common stock. Additionally, 20,000 shares are indirectly beneficially owned by a Trust. Mr. Pande also holds 66,681 derivative securities in the form of stock options.For deeper insights into Immunovant’s valuation and performance, InvestingPro offers 13 additional ProTips and comprehensive Pro Research Reports covering over 1,400 US equities.

In other recent news, Immunovant has been the subject of several positive analyst updates. H.C. Wainwright raised its price target for Immunovant shares to $40, maintaining a Buy rating, based on promising response rates from the company’s Phase 2 rheumatoid arthritis study. This study reported significant response rates, with 72.7% achieving ACR20, 54.5% ACR50, and 35.8% ACR70 at week 16 among 165 highly refractory patients. Similarly, BofA Securities increased its price target to $43, also maintaining a Buy rating, citing an improved peak sales outlook for IMVT-1402, now projected at $6.8 billion. This outlook is driven by potential contributions from treatments for Graves’ disease and challenging cases of rheumatoid arthritis. Stifel reaffirmed its Buy rating and $49 price target, emphasizing the trial’s high response rates and the complexity of cross-trial comparisons due to patient enrichment strategies. Additionally, Roivant Sciences, which includes Immunovant in its portfolio, reported its fourth-quarter earnings for fiscal year 2026. While Roivant missed its earnings per share expectations, the company highlighted a strong cash position and strategic growth in its product pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.